Business Wire

NY-CALVIN-KLEIN-INC

3.8.2020 13:02:08 CEST | Business Wire | Press release

Share
Calvin Klein Fragrances Announces the Return of Christy Turlington Burns and Edward Burns as the Faces of ETERNITY Calvin Klein

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today revealed the worldwide global advertising campaign for ETERNITY Calvin Klein with the return of maternal health activist and model Christy Turlington Burns, alongside her husband, director, writer, producer and actor Edward Burns, as the faces of the ETERNITY campaign.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005090/en/

ETERNITY Calvin Klein advertising has artfully and unforgettably captured the promise of romance, intimacy, and commitment. Together, Turlington Burns who starred in the first ETERNITY advertising campaign when it debuted in 1988, and Burns who has appeared next to his wife in the 2014 and 2016 campaigns, bring to life the essence of the ETERNITY love story with their timeless relationship.

Today, the ETERNITY story continues with the iconic couple in a new television and print campaign that portrays an enduring love rooted in sensuality, authenticity, spontaneity, and supports the launch of the new ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein.

“After shooting the first ETERNITY Calvin Klein campaign ever over 30 years ago, it’s a pleasure to be working with Calvin Klein again and to continue to be a part of the history of such an iconic fragrance,” said Turlington Burns + Burns jointly. “We are honored to be part of this new campaign celebrating our relationship with ETERNITY Calvin Klein.”

The television campaign is captured by filmmaker and photographer Matt Lambert and is a combination of traditional black and white in addition to color shots. This juxtaposition conveys their committed past with the strength of their present relationship. The campaign, a compilation of joyful moments by the ocean, is an homage to their love story and is set to a reimagined cover of the iconic love song ‘Unchained Melody’ by Lykke Li.

Lachlan Bailey photographed the iconic couple in a classic black and white still campaign visual on the beach. Turlington Burns' hair is effortlessly being swept back by the ocean breeze while Burns adoringly pulls her toward him. The image is just one of many memories in time for the couple, a stolen moment in their endless love story.

“We are thrilled to welcome back such an iconic couple to celebrate the next chapter of ETERNITY Calvin Klein which continues its legacy as one of the most beloved fragrances for both men and women,” said Simona Cattaneo, President of Luxury Brands at Coty. “With this new campaign ETERNITY continues to inspire timeless love; its romantic values are undimmed by the passing of time and still resonate with consumers today.”

In addition to supporting ETERNITY Calvin Klein Signature, the campaign also supports the new line extension ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein through the still campaign visual also shot by Bailey. The hero image is an injection of happiness and bursts of freshness; Turlington Burns and Burns are captured playfully frolicking in the ocean, holding each other closely as the waves splash around them.

Evoking the free-spirited nature of the ocean and the joy of strolling through a beautiful sensual garden, the line extension inspires spontaneity while celebrating the spirit of eternal love. The enduring legacy of the ETERNITY Calvin Klein Signature is playfully reimagined for modern lovers with fresh green ingredients in ETERNITY Cologne for him Calvin Klein by perfumers Julie Massé, Ralf Schwieger and Véronique Nyberg of Mane and romantic watery florals in ETERNITY Eau Fresh for her Calvin Klein by perfumers Olivier Gillotin and Sonia Constant of Givaudan.

ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein are available for sale globally starting today on a rolling basis.

About Calvin Klein, Inc.:

CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.

Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $9 billion in 2019 and were distributed in over 110 countries. Calvin Klein employs over 11,500 associates globally. We were acquired by PVH Corp. in 2003.

About COTY Inc.

Coty is one of the world’s largest beauty companies with approximately $9 billion in revenue, with a purpose to celebrate and liberate the diversity of consumers’ beauty. Its strong entrepreneurial heritage has created an iconic portfolio of leading beauty brands. Coty is the global leader in fragrance, a strong number two in professional salon hair color & styling, and number three in color cosmetics. Coty operates three divisions – Coty Consumer Beauty, which is focused on color cosmetics, retail hair coloring and styling products, body care and mass fragrances sold primarily in the mass retail channels with brands such as Bourjois, Max Factor, Rimmel, Wella, Adidas and Guess; Coty Luxury, which is focused on prestige fragrances and skincare with brands such as Gucci, Hugo Boss, Calvin Klein, Chloe, Bottega Veneta and Alexander McQueen; and Coty Professional Beauty, which is focused on servicing salon owners and professionals in both hair and nail, with brands such as Wella Professionals, System Professional, OPI and ghd. Coty has approximately 20,000 colleagues globally and its products are sold in over 130 countries. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .

ADVERTISING CREDITS:

Creative Direction: Calvin Klein and Mazarine
Campaign Videos: Matt Lambert
Advertising Campaign images: Lachlan Bailey

EDITORIAL CREDIT:

ETERNITY For Women Eau de Parfum CALVIN KLEIN
ETERNITY For Men Eau de toilette CALVIN KLEIN
ETERNITY Eau Fresh for her CALVIN KLEIN
ETERNITY Cologne for him CALVIN KLEIN

TVC: https://youtu.be/NN9Q2pKiDKE

SOCIAL MEDIA: #cketernity

BRAND HANDLE: @calvinklein

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye